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ABSTRACT2
The ‘Laser-hybrid Accelerator for Radiobiological Applications’, LhARA, is conceived as a novel,3
flexible facility dedicated to the study of radiobiology. The technologies demonstrated in LhARA,4
which have wide application, will be developed to allow particle-beam therapy to be delivered in5
a new regimen, combining a variety of ion species in a single treatment fraction and exploiting6
ultra-high dose rates. LhARA will be a hybrid accelerator system in which laser interactions drive7
the creation of a large flux of protons or light ions that are captured using a plasma (Gabor)8
lens and formed into a beam. The laser-driven source allows protons and ions to be captured9
at energies significantly above those that pertain in conventional facilities, thus evading the10
current space-charge limit on the instantaneous dose rate that can be delivered. The laser-hybrid11
approach, therefore, will allow the radiobiology that determines the response of tissue to ionising12
radiation to be studied with protons and light ions using a wide variety of time structures, spectral13
distributions, and spatial configurations at instantaneous dose rates up to and significantly beyond14
the ultra-high dose-rate ‘FLASH’ regime.15
It is proposed that LhARA be developed in two stages. In the first stage, a programme of in16
vitro radiobiology will be served with proton beams with energies between 10 MeV and 15 MeV.17
In stage two, the beam will be accelerated using a fixed-field accelerator (FFA). This will allow18
experiments to be carried out in vitro and in vivo with proton beam energies of up to 127 MeV.19
In addition, ion beams with energies up to 33.4 MeV per nucleon will be available for in vitro20
and in vivo experiments. This paper presents the conceptual design for LhARA and the R&D21
programme by which the LhARA consortium seeks to establish the facility.22
LAY SUMMARY23
It is well established that radiation therapy (RT) is an effective treatment for many types of cancer.24
Most treatments are delivered by machines that accelerate electrons which are then used to25
produce a beam of high-energy photons (X-rays) which are directed at a tumour to kill cancer26
cells. However, healthy tissue anywhere in the path of the photon beam is also irradiated and so27
can be damaged. Modern X-ray therapy is able to reduce this damage by using several beams at28
different angles.29
Recent years have seen the use of a new type of machine in which protons are accelerated to30
produce proton beams (rather than photon beams) which are directed at a tumour. These proton31
beams can be arranged to deposit almost all of their energy in a small volume within a tumour so32
they cause little damage to healthy tissue; a major advantage over photon beams. But proton33
machines are large and expensive, so there is a need for the development of proton machines34
that are smaller, cheaper and more flexible in how they can be used.35
The LhARA project is aimed at the development of such proton machines using a new approach36
based on high powered lasers. Such new machines could also make it easier to deliver the dose37
in very short high-intensity pulses and as a group of micro-beams—exciting recent research has38
shown that this brings improved effectiveness in killing cancer cells while sparing healthy tissue.39
The technology to be proved in LhARA should enable a course of RT to be delivered in days40
rather than weeks.41
Scientifically, there is a need to understand better the basic processes by which radiation42
interacts with biological matter to kill cancer cells—the investigation of these processes involves43
physics as well as biology. Thus the most important aim of LhARA is to pursue this radiobiological44
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research in new regimens and from this to develop better treatments. LhARA will also pursue45
technological research into laser-hybrid accelerators.46
Keywords: Radiobiology, Novel acceleration, Proton beam therapy, Ion beam therapy, Laser-driven acceleration, Plasma lens, Fixed47
field alternating gradient acceleration48
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1 INTRODUCTION
Cancer is the second most common cause of death globally [The World Health Organisation (2020)]. In49
2018, 18.1 million new cancer cases were diagnosed, 9.6 million people died of cancer-related disease, and50
43.8 million people were living with cancer [Bray et al. (2018); Fitzmaurice et al. (2018)]. It is estimated51
that 26.9 million life-years could be saved in low- and middle-income countries if radiotherapy capacity52
could be scaled up [Atun et al. (2015)]. Novel techniques incorporated in facilities that are at once robust,53
automated, efficient, and cost-effective are required to deliver the required scale-up in provision.54
Radiation therapy (RT), a cornerstone of cancer treatment, is used in over 50 % of cancer patients [Datta55
et al. (2019)]. The most frequently used types of radiotherapy employ photon or electron beams with56
MeV-scale energies. Proton and ion beams offer substantial advantages over X-rays because the bulk of57
the beam energy is deposited in the Bragg peak. This allows dose to be conformed to the tumour while58
sparing healthy tissue and organs at risk. The benefits of proton and ion-beam therapy (PBT) are widely59
recognised. PBT today is routinely delivered in fractions of ∼ 2Gy per day over several weeks; each60
fraction being delivered at a rate of <∼ 5Gy/minute deposited uniformly over the target treatment volume.61
Evidence of therapeutic benefit when dose is delivered at ultra-high rate, >∼ 40Gy/s, in “FLASH” RT [Berry62
(1973); Favaudon et al. (2014); Durante et al. (2018); Vozenin et al. (2019); Wilson et al. (2020b)] or63
when multiple micro-beams with diameter less than 1 mm distributed over a grid with inter-beam spacing64
∼ 3mm are used [Prezado and Fois (2013); Prezado et al. (2017b,a, 2018); Gonza´lez and Prezado (2018);65
Martı´nez-Rovira et al. (2017)]. However, the radiobiological mechanisms by which the therapeutic benefit66
is generated using these approaches are not entirely understood.67
LhARA, the Laser-hybrid Accelerator for Radiobiological Applications, is conceived as the new, highly68
flexible, source of radiation that is required to explore the mechanisms by which the biological response to69
ionising radiation is determined by the physical characteristics of the beam. A high-power pulsed laser will70
be used to drive the creation of a large flux of protons or light ions which are captured and formed into a71
beam by strong-focusing plasma lenses. The plasma (Gabor) lenses provide the same focusing strength72
as high-field solenoids at a fraction of the cost. Rapid acceleration will be performed using a fixed-field73
alternating-gradient accelerator (FFA) thereby preserving the unique flexibility in the time, energy, and74
spatial structure of the beam afforded by the laser-driven source.75
The LhARA facility may be developed in two stages. In the first stage, the laser-driven beam, captured76
and transported using plasma lenses and bending magnets, will serve a programme of in vitro radiobiology77
with proton beams of energy of up to 15 MeV. In stage two, the beam will be accelerated using an FFA. This78
will allow experiments to be carried out in vitro and in vivo with proton-beam energies of up to 127 MeV.79
Ion beams (including C6+) with energies up to 33.4 MeV per nucleon will also be available.80
The laser pulse that initiates the production of protons or ions at LhARA may be triggered at a repetition81
rate of up to 10 Hz. The time structure of the beam may therefore be varied to interrupt the chemical82
and biological pathways that determine the biological response to ionising radiation with 10 ns to 40 ns83
long proton or ion bunches repeated at intervals as small as 100 ms. The technologies chosen to capture,84
transport, and accelerate the beam in LhARA ensure that this unique capability is preserved. The LhARA85
beam may be used to deliver an almost uniform dose distribution over a circular area with a maximum86
diameter of between 1 cm and 3 cm. Alternatively, the beam can be focused to a spot with diameter of87
∼ 1mm.88
The technologies demonstrated in LhARA have the potential to be developed to make particle-beam89
therapy (PBT) available to the many. The laser-hybrid approach will allow radiobiological studies and90
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eventually radiotherapy to be carried out in completely new regimens, delivering a variety of ion species in91
a broad range of time structures, spectral distributions, and spatial configurations at instantaneous dose92
rates up to and potentially significantly beyond the current ultra-high dose-rate “FLASH” regime.93
The “pre Conceptual Design Report” (pre-CDR) for LhARA [The LhARA consortium (2020)] lays the94
foundations for the development of full conceptual and technical designs for the facility. The pre-CDR also95
contains a description of the R&D that is required to demonstrate the feasibility of critical components96
and systems. This paper presents a summary of the contents of the pre-CDR and lays out the vision of the97
consortium.98
99
2 MOTIVATION
RT delivered using protons and ions, particle-beam therapy (PBT), has the potential to overcome some100
of the fundamental limitations of X-rays in cancer treatment through targeted delivery of the radiation101
dose [Loeffler and Durante (2013)]. The Particle Therapy Co-Operative Group (PTCOG) currently lists102
90 proton therapy facilities and 12 carbon ion therapy facilities, located predominantly in high-income103
countries [PTCOG (2020)]. Low- and middle-income countries (LMIC) are relatively poorly served, indeed104
nearly 70% of cancer patients globally do not have access to RT [Datta et al. (2019)].105
The case for a systematic study of the radiobiology of proton and ion beams106
The efficacy of proton and ion beams is characterised by their relative biological effectiveness (RBE) in107
comparison to a reference photon beam. The treatment-planning software that is in use in the clinic today108
assumes an RBE value for protons of 1.1 [Paganetti and van Luijk (2013)], meaning that, compared to109
X-rays, a lower dose of protons is needed to produce the same therapeutic effect. However, the rapid110
rise in the linear energy transfer (LET) at the Bragg peak leads to significant uncertainties in the RBE.111
Furthermore, it is known that RBE depends strongly on many factors, including particle energy, dose, dose112
rate, the degree of hypoxia, and tissue type [Paganetti (2014)]. Indeed, RBE values from 1.1 to over 3113
have been derived from in vitro clonogenic-survival assay data following proton irradiation of cultured114
cell lines derived from different tumours [Paganetti (2014); Chaudhary et al. (2014); Wilkens and Oelfke115
(2004)]. RBE values of ∼ 3 are accepted for high-LET carbon-ion irradiation, although higher values have116
been reported [Karger and Peschke (2017)]. RBE uncertainties for carbon and other ion species are at117
least as large as they are for protons. These uncertainties can lead to an incorrect estimation of the dose118
required to treat a particular tumour. Overestimation can lead to risk of damage to healthy tissue, while an119
underestimate can lead to the tumour not being treated sufficiently for it to be eradicated.120
The radio-therapeutic effect is caused largely by irreparable damage to the cell’s DNA. The spectrum of121
DNA damage induced within tumour cells changes in response to differences in RBE. Larger RBE values,122
corresponding to higher LET, can increase the frequency and complexity of DNA damage, particularly123
DNA double-strand breaks (DSB) and complex DNA damage (CDD) where multiple DNA lesions are124
induced in close proximity [Vitti and Parsons (2019); Carter et al. (2018)]. These DNA lesions are a major125
contributor to radiation-induced cell death as they represent a significant barrier to the cellular DNA-repair126
machinery [Vitti and Parsons (2019)]. However, a number of other biological factors contribute to varying127
RBE in specific tumours, including the intrinsic radio-sensitivity of the tissue, the level of oxygenation128
(hypoxia), the growth and re-population characteristics, and the associated tumour micro-environment.129
Consequently there is still significant uncertainty in the precise radiobiological mechanisms that arise and130
how these mechanisms are affected by PBT. Detailed systematic studies of the biophysical effects of the131
interaction of protons and ions, under different physical conditions, with different tissue types will provide132
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important information on RBE variation and could enable enhanced patient treatment-planning algorithms133
to be devised. In addition, studies examining the impact of combination therapies with PBT (e.g. targeting134
the DNA damage response, hypoxia signalling mechanisms and also the tumour micro-environment) are135
currently sparse; performing these studies will therefore provide input vital to the development of future136
personalised patient-therapy strategies using PBT.137
The case for novel beams for radiobiology138
PBT delivery to date has been restricted to a small range of beam characteristics. Significantly reduced139
lung fibrosis in mice, skin toxicity in mini-pigs, and reduced side-effects in cats with nasal squamous-cell140
carcinoma have been observed which is currently thought to be mediated via local oxygen depletion [Wilson141
et al. (2020b,a)]. In fact, the first patient with CD30+ T-cell cutaneous lymphoma has been safely treated142
with electrons delivered at FLASH dose rates [Bourhis et al. (2019)]. In addition, therapeutic benefit has143
been demonstrated with the use of multiple micro-beams [Prezado et al. (2017b)]. However, there is still144
significant uncertainty regarding the thresholds and the radiobiological mechanisms by which therapeutic145
benefit is generated in FLASH and micro-beam therapy. Extensive further study both in vitro and in146
appropriate in vivo models is required.147
The LhARA facility will provide access to stable ion beams, provide a wide variety of temporal,148
spatial, and spectral fractionation schemes, and deliver reliable and reproducible biological data with149
fewer constraints than at current clinical centres. The availability of several ion beams (from protons to150
heavier ions) within the same facility will provide further flexibility, and the ability to perform direct151
radiobiological comparisons of the effects of different charged particles at different energies and dose152
rates, and to perform mechanistic studies (e.g. examining the oxygen depletion hypothesis for FLASH)153
will be unique. In addition, LhARA will enable exhaustive evaluations of RBE using more complex154
end-points (e.g. angiogenesis and inflammation) in addition to routine survival measurements. The ability155
to evaluate charged particles in conjunction with other therapies (immunotherapy and chemotherapy), and156
of performing in vivo experiments with the appropriate animal models is a huge advantage given the current157
lack of evidence in these areas. LhARA therefore has the potential to provide the radiobiological data158
required to improve clinical practice. The simulations of LhARA that are described in this document have159
been used to estimate the dose delivered as a function of energy for protons and carbon ions. Details of the160
simulations can be found in sections 3.3 and 3.4. The simulations show instantaneous particle rates of the161
order of 109 particles per shot can be achieved, corresponding to average dose rates of up to >∼ 120Gy/s162
for protons and >∼ 700Gy/s for carbon ions. These estimates are based on the baseline specifications for163
LhARA.164
Laser-hybrid beams for radiobiology and clinical application165
High-power lasers have been proposed as an alternative to conventional proton and carbon-ion facilities for166
radiotherapy [Bulanov et al. (2002); Fourkal et al. (2003); Malka et al. (2004)]. Laser-driven sources have167
also been proposed to serve as the basis of electron, proton and ion-beams for radiobiology [Kraft et al.168
(2010); Fiorini et al. (2011); Yogo et al. (2011); Bin et al. (2012); Doria et al. (2012); Zeil et al. (2013);169
Masood et al. (2014); Zlobinskaya et al. (2014)]. While a number of cell irradiation experiments have been170
conducted with laser-accelerated ions [Doria et al. (2012); Zeil et al. (2013); Pommarel et al. (2017); Manti171
et al. (2017)], these have been limited in scope to a single-shot configuration. More recent projects (e.g.172
A-SAIL [A-SAIL Project (2020)], ELI [Cirrone et al. (2013)] and SCAPA [Wiggins et al. (2019)]) will also173
investigate radiobiological effects using laser-driven ion beams. These studies will also address various174
technological issues [Manti et al. (2017); Romano et al. (2016a); Masood et al. (2017); Chaudhary et al.175
(2017); Margarone et al. (2018)].176
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A beam line to provide ion-driven beams for multi-disciplinary applications, ELIMAIA (ELI177
Multidisciplinary Applications of laser-Ion Acceleration) is being brought into operation at the Extreme178
Light Infrastructure (ELI) [Cirrone et al. (2020); Schillaci et al. (2019)]. This beam line will include the179
“ELI MEDical and multidisciplinary applications” (ELIMED) beam line which will allow radiobiological180
investigations to be carried out [Cirrone et al. (2016); Romano et al. (2016b); Milluzzo et al. (2017); Pipek181
et al. (2017); Milluzzo et al. (2018); Cirrone et al. (2020)]. LhARA is distinguished from this facility in182
that the energy at which the beam will be captured has been chosen to maximise the shot-to-shot stability183
of the particle flux.184
Protons and ions at conventional facilities are captured at energies of several tens of keV. At such low185
energies the mutual repulsion of the particles, the “space-charge effect”, limits the maximum instantaneous186
dose rate. The laser-driven source allows protons and ions to be captured at energies significantly above187
those that pertain in conventional facilities, thus evading the current space-charge limit. Rapid acceleration188
will be performed using a fixed-field alternating-gradient accelerator (FFA) thereby preserving the unique189
flexibility in the time, energy, and spatial structure of the beam afforded by the laser-driven source. Modern190
lasers are capable of delivering a Joule of energy in pulses that are tens of femtoseconds in length at191
repetition rates of >∼ 10Hz. Laser-driven ion sources create beams that are highly divergent, have a large192
energy spread, and an intensity that can vary by up to 25% pulse-to-pulse [Dover et al. (2020)]. These193
issues are addressed in the conceptual design through the use of Gabor lenses to provide strong focusing194
and to allow energy selection. In addition, sophisticated instrumentation will be used in a fast feedback-195
and-control system to ensure that the dose delivered is both accurate and reproducible. This approach will196
allow multiple ion species, from proton to carbon, to be produced from a single laser by varying the target197
foil and particle-capture optics.198
LhARA will prove the principle of the novel technologies required for the development of future therapy199
facilities. The legacy of the LhARA programme will therefore be: a unique facility dedicated to the200
development of a deep understanding of the radiobiology of proton and ion beams; and the demonstration201
in operation of technologies that will allow PBT to be delivered in completely new regimes.202
203
3 THE LHARA FACILITY
The LhARA facility, shown schematically in figure 1, has been designed to serve two end stations for204
in vitro radiobiology and one end station for in vivo studies. The principle components of the LhARA205
accelerator are: the laser-driven proton and ion source; the matching and energy selection section; beam206
delivery to the low-energy in vitro end station; the low-energy abort line; the injection line for the fixed-207
field alternating-gradient accelerator (FFA); the FFA; the extraction line; the high-energy abort line; beam208
delivery to the high-energy in vitro end station; and the transfer line to the in vivo end station. Proton beams209
with energies of between 12 MeV and 15 MeV will be delivered directly from the laser-driven source to210
the low-energy in vitro end station via a transfer line. The high-energy in vitro end station and the in vivo211
end station will be served by proton beams with energy between 15 MeV and 127 MeV and by ion beams,212
including C6+ with energies up to 33.4 MeV/u. The design parameters for the various components of213
LhARA are given in tables 1 and 2. The design of the LhARA facility is described in the sections that follow.214
215
3.1 Laser-driven proton and ion source216
A novel solution for ion-acceleration is to use a compact, flexible laser-driven source coupled to a state-217
of-the-art beam-transport line. This allows an accelerating gradient of >∼ 10GV/m to be exploited at the218
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In vivo beam line 
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manipulation
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Beam Dump
Kicker Magnet
Figure 1. Schematic diagram of the LhARA beam lines. The particle flux from the laser-driven source is
shown by the red arrow. Folowing the ‘Capture’ section is followed by the ‘Matching and energy selection’
sections, the beam is directed either into the 90◦ bend that takes it to the low-energy in vitro end station,
towards the FFA injection line, or to the low-energy beam dump. Post acceleration is performed using the
FFA on extraction from which the beam is directed either to the high-energy in vitro end station, the in vivo
end station, or the high-energy beam dump. Gabor lenses are shown as orange cylinders, RF cavities as
grey cylinders, octopole magnets as green discs, collimators as dark-green bars, dipole magnets are shown
in blue, quadrupole magnets are shown in red, beam dumps (black rectangles) and kicker magnets are also
shown.
laser-driven source. We propose to operate in a laser-driven sheath-acceleration regime [Clark et al. (2000a);219
Snavely et al. (2000); Daido et al. (2012)] for ion generation. An intense, short laser pulse will be focused220
onto a target. The intense electric field generated on the front surface of the target accelerates the surface221
electrons, driving them into the material. Electrons which gain sufficient energy traverse the target, ionising222
the material as they go. A strong space-charge electric field, the ‘sheath’, is created as the accelerated223
electrons exit the rear surface of the target. This field in turn accelerates surface-contaminant ions. The224
sheath-acceleration scheme has been shown to produce ion energies greater than 40 MeV/u at the highest225
laser intensities. The maximum proton energy (Ep) scales with laser intensity (I) as, Ep ∝ I 12 . The laser226
required to deliver a significant proton flux at 15 MeV is commercially available.227
The distribution of proton and ion energies observed in laser-driven beams exhibits a sharp cut off at228
the maximum energy and, historically, the flux of laser-accelerated ion beams has varied significantly229
shot-to-shot. To reduce the impact of the shot-to-shot variations, the choice has been made to select particles230
from the plateau of the two-temperature energy spectrum of the laser-accelerated ion beam [Clark et al.231
(2000b); Passoni et al. (2010)]. This choice should enhance ion-beam stability and allow reproducible232
measurements to be carried out at ultra-high dose rates using a small number of fractions. To create the flux233
required in the plateau region it is proposed that a 100 TW laser system is used. A number of commercial234
lasers are available that are capable of delivering > 2.5 J in pulses of duration < 25 fs, at 10 Hz with235
contrast better than 1010 : 1. Shot-to-shot stability of < 1% is promised, an important feature for stable236
ion-beam production.237
Target238
Key to the operation of this configuration is a system that refreshes the target material at high-repetition239
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Table 1. Design parameters of the components of the LhARA facility. The parameter table is provided
in a number of sections. This section contains parameters for the Laser-driven proton and ion source, the
Proton and ion capture section, and the Stage 1 beam transport section.
Parameter Value or range Unit
Laser driven proton and ion source
Laser power 100 TW
Laser Energy 2.5 J
Laser pulse length 25 fs
Laser rep. rate 10 Hz
Required maximum proton energy 15 MeV
Proton and ion capture
Beam divergence to be captured 50 mrad
Gabor lens effective length 0.857 m
Gabor lens length (end-flange to end-flange) 1.157 m
Gabor lens cathode radius 0.0365 m
Gabor lens maximum voltage 65 kV
Number of Gabor lenses 2
Alternative technology: solenoid length 1.157 m
Alternative technology: solenoid max field
strength
1.3 T
Stage 1 beam transport: matching & energy selection, beam delivery to low-energy end station
Number of Gabor lenses 3
Number of re–bunching cavities 2
Number of collimators for energy selection 1
Arc bending angle 90 Degrees
Number of bending magnets 2
Number of quadrupoles in the arc 6
Alternative technology: solenoid length 1.157 m
Alternative technology: solenoid max field
strength (to serve the injection line to the
Stage 2)
0.8 (1.4) T
rate in a reproducible manner. A number of schemes have been proposed for such studies, from high-240
pressure gases [Willingale et al. (2009); Bin et al. (2015); Chen et al. (2017)], cryogenic hydrogen ribbons241
[Margarone et al. (2016); Gauthier et al. (2017); Obst et al. (2017)], liquid sheets [Morrison et al. (2018)]242
and tape drives [Noaman-ul Haq et al. (2017)]. For the LhARA facility, a tape drive based on the system243
developed at Imperial College London is proposed. This system is capable of reliable operation at target244
thicknesses down to 5µm, using both aluminium and steel foils, and down to 18µm using plastic tapes.245
Such tape-drive targets allow operation at high charge (up to 100 pC at 15± 1MeV, i.e. > 109 protons per246
shot) and of delivering high-quality proton and ion fluxes at repetition rates of up to 10 Hz or greater.247
The careful control of the tension on the tape in a tape-drive target is critical for reproducible operation.248
The tape must be stretched to flatten the surface, without stretching it to its plastic response. Surface249
flatness is important for a number of reasons. Rippling of the front surface modifies the laser absorption250
dramatically; uncharacterised rippling can make shot-to-shot variations significant and unpredictable251
[Noaman-ul Haq et al. (2017)]. Similarly, rear surface perturbations can modify the sheath field, resulting252
in spatial non-uniformities of the proton beam or suppression of the achievable peak energies. Tape drives253
with torsion control and monitoring to maintain a high-quality tape surface have been designed and operated254
in experiments at Imperial College London. The development of these targets continues with a view to the255
production of new, thinner tapes for improved ion generation and the creation of ion species other than256
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Table 2. Design parameters of the components of the LhARA facility. The parameter table is provided in
a number of sections. This section contains parameters for the Stage 2 beam transport and the in vitro and
in vivo end stations.
Parameter Value or range Unit
Stage 2 beam transport: FFA, transfer line, beam delivery to high-energy end stations
Number of bending magnets in the injection
line
7
Number of quadrupoles in the injection line 10
FFA: Machine type single spiral scaling FFA
FFA: Extraction energy 15–127 MeV
FFA: Number of cells 10
FFA: Orbit Rmin 2.92 m
FFA: Orbit Rmax 3.48 m
FFA: Orbit excursion 0.56 m
FFA: External R 4 m
FFA: Number of RF cavities 2
FFA: RF frequency 1.46–6.48 MHz
FFA: harmonic number 1, 2 or 4
FFA: RF voltage (for 2 cavities) 4 kV
FFA: spiral angle 48.7 Degrees
FFA: Max B field 1.4 T
FFA: k 5.33
FFA: Magnet packing factor 0.34
FFA: Magnet opening angle 12.24 degrees
FFA: Magnet gap 0.047 m
FFA: Ring tune (x,y) (2.83,1.22)
FFA: γT 2.516
FFA: Number of kickers 2
FFA: Number of septa 2
Number of bending magnets in the extraction
line
2
Number of quadrupoles in the extraction line 8
Vertical arc bending angle 90 Degrees
Number of bending magnets in the vertical
arc
2
Number of quadrupoles in the vertical arc 6
Number of cavities for longitudinal phase
space manipulation
5
Number of quadrupoles in the in vivo beam
line
4
In vitro biological end stations
Maximum input beam diameter 1-3 cm
Beam energy spread (full width) Low-energy end station: ≤ 4 %
High-energy end station: ≤ 1 %
Input beam uniformity < 5 %
Scintillating fibre layer thickness 0.25 mm
Air gap length 5 mm
Cell culture plate thickness 1.3 mm
Cell layer thickness 0.03 mm
Number of end stations 2
In vivo biological end station
Maximum input beam diameter 1-3 cm
Beam energy spread (full width) ≤ 1 %
Input beam uniformity < 5 %
Beam options Spot-scanning, passive
scattering, micro-beam
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Figure 2. Schematic diagram of a Penning-Malmberg trap of the type proposed for use in the Gabor lenses
to be used in LhARA. The solenoid coils, and the direction of current flow, are indicated by the red circles.
The confining electrostatic potential is provided using a central cylindrical anode and two cylindrical
negative end electrodes. The ion beam enters on-axis from the left and the electron cloud is indicated by
the green shaded area.
proton and carbon. This is an active area of R&D that will continue with the development of LhARA.257
258
3.2 Proton and ion capture259
The use of an electron cloud as a focusing element for charged-particle beams was first proposed by260
Gabor [Gabor (1947)]. The electron could is confined within the lens using a long cylindrical anode placed261
within a uniform solenoid field, see figure 2. Such a configuration is commonly known as a ‘Penning262
trap’ and has found wide application in many fields [Thompson (2015)]. Variations on the Penning trap263
where axial apertures in the cathodes are introduced, such as the Penning-Malmberg trap [deGrassie and264
Malmberg (1980); Malmberg et al. (1988)] are attractive for beam-based applications due to the excellent265
access provided to the plasma column.266
The focal length of a Gabor lens of length l is given in terms of the electron number density by:267
1
f
=
e2ne
40U
l ; (1)
where e is the magnitude of the electric charge of the electron, ne is the number density of the electrons268
confined within the lens, 0 the permittivity of free space, and U is the kinetic energy of the particle beam.269
The desired focussing strength determines ne which in turn allows the anode voltage and magnetic-field270
strength to be determined [Reiser (1989); Pozimski and Aslaninejad (2013)]. The focal length of the Gabor271
lens is inversely proportional to the number density of electrons trapped in the cloud. The focal lengths272
desired to capture the proton and ion beams at LhARA have been chosen such that the required electron273
number densities are conservative and lie within the range achieved in published experiments.274
For a given focal length, the magnetic field required in the Gabor lens is reduced compared to that of a275
solenoid that would give equivalent focusing. In the non-relativistic approximation the relationship between276
the magnetic field in the Gabor lens, BGBL, and the equivalent solenoid, Bsol, is given by [Pozimski and277
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Aslaninejad (2013)]:278
BGPL = Bsol
√
Z
me
mp
; (2)
where Z is the charge state of the ions. In the case of a proton beam the reduction factor is 43. This means279
the cost of the solenoid for a Gabor lens can be significantly lower than the cost for a solenoid of equivalent280
focusing strength.281
Instability of the electron cloud is a concern in the experimental operation of a Gabor lens; azimuthal282
beam disruption due to the diocotron instability has been observed and described theoretically [Meusel et al.283
(2013)]. Theory indicates that the diocotron instability is most problematic under well-defined geometric284
conditions. The reliable operation of a Gabor lens in a regime free from this instability has yet to be285
demonstrated. Gabor lenses promise very strong focusing, simple construction, and low magnetic field,286
all attractive features for LhARA. However, these attractive features come at the cost of relatively high287
voltage operation ( >∼ 50 kV) and possible vulnerability to instability.288
With reliable operation of Gabor lenses as yet unproven, we plan a two-part experimental and theoretical289
programme of research to prove Gabor-lens suitability. Initial work will include: theoretical investigation290
of lens stability in a full 3D particle-in-cell code such as VSIM [VSI (2020)]; and the development of291
electron-density diagnostics based on interferometric measurement of the refractive-index change. A test292
Gabor lens will be constructed to allow validation of both the simulation results and a new diagnostic using293
an alpha emitter as a proxy for the LhARA beam. In addition, the initial investigation will include the294
design of an electron beam to fill the lens. Should it prove not to be possible to produce a suitable Gabor295
lens it will be necessary to use high-field solenoids to produce the equivalent focusing effect.296
297
3.3 Beam transport and delivery to the low-energy in vitro end station298
Beam-transport to the low-energy in vitro end station is required to deliver a uniform dose distribution at299
the cell layer. Beam losses must be minimised for radiation safety and to maximise the dose that can be300
delivered in a single shot. The transport line has been designed to minimise regions in which the beam301
is brought to a focus to reduce the impact of space-charge forces on the beam phase-space. An optical302
solution was initially developed using Beamoptics [Autin et al. (1998)] and MADX [Grote and Schmidt303
(2003)]. Accurate estimation of the performance of the beam line requires the inclusion of space-charge304
forces and particle-matter interactions. Therefore, performance estimation was performed using Monte305
Carlo particle-tracking from the ion source to the end station. BDSIM [Nevay et al. (2020)], which is based306
on the Geant4 toolkit was used for the simulation of energy deposition arising from beam interactions with307
the material in the accelerator and the end station. GPT [De Loos and Van der Geer (1996)] was used for308
evaluating the full 3D impact of space-charge.309
An idealised Gaussian beam was generated with a spot size of 4µm FWHM, an angular divergence of310
50 mrad, 35 fs FWHM bunch length, and an energy spread of 1 × 10−6 MeV. The maximum estimated311
bunch charge is 1× 109 protons. The presence of a substantial electron flux produced from the laser target312
compensates the high proton charge density in the vicinity of the ion-production point. To approximate the313
partial space-charge compensation in the vicinity of the target it was assumed that co-propagating electrons314
would fully compensate the space-charge forces over the first 5 cm of beam propagation. Beyond this, the315
proton beam was assumed to have separated from the co-propagating electrons sufficiently for space-charge316
to become a prominent effect and cause emittance growth. Therefore, a further 5 cm drift was simulated317
including space-charge forces. At a distance of 10 cm from the ion source the beam is at the exit of the318
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Figure 3. Beam transport for Stage 1 of LhARA visualised in BDSIM, showing five machine sections. The
capture section is composed of two Gabor lenses (orange cylinders). The matching and energy selection
section includes three Gabor lenses, two RF cavities (grey cylinders) and an octupole magnet (green disc).
The beam shaping and extraction section includes a second octupole and a collimator (vertical dark-green
bar). The vertical matching arc directs the beam into the low-energy in vitro end station and is composed of
two 45◦ dipoles (blue and brown) and six quadrupoles (red). The total length of this beam line is 17.3 m.
laser-target vessel. The kinematic distributions of ions in the beam were stored at this point and passed to319
the relevant BDSIM and GPT simulations of the downstream beam line.320
The beam line, shown schematically in figure 3, is composed of five sections: beam capture; matching321
and energy selection; beam shaping; vertical arc matching; and an abort line. The capture section uses two322
Gabor lenses to minimise the transverse momentum of particles in the beam. Beyond the capture section,323
an RF cavity permits control of the bunch length and manipulation of the longitudinal phase-space. A third324
Gabor lens then focuses the bunch to a small spot size after which a second RF cavity is located to provide325
further longitudinal phase-space manipulation. Two further Gabor lenses bring the beam parallel once more326
in preparation for the vertical 90◦ arc. All Gabor lenses have an inner radius of 3.65 cm and an effective327
length of 0.857 m. All lenses operate at a cathode voltage of less than 65 kV.328
A parallel beam emerges from the final Gabor lens, providing significant flexibility for the inclusion329
of beam shaping and extraction systems. Beam uniformity will be achieved using octupole magnets to330
provide third-order focusing to perturb the first-order focusing from the Gabor lenses. Such schemes have331
been demonstrated in magnetic lattices in a number of facilities [Tsoupas et al. (1991); Urakabe et al.332
(1999); Amin et al. (2018)]. A suitable position for the first octupole was identified to be after the final333
Gabor lens where the beam is large; its effect on the beam is expected to be significant. Octupoles were334
only modelled in BDSIM as GPT does not have a standard component with an octupolar field. The typical335
rectangular transverse distribution resulting from octupolar focusing requires collimation to match the336
circular aperture through which the beam enters the end station. A collimator is therefore positioned at the337
start of the vertical arc. Further simulations are required to determine the optimum position of the second338
octupole and to evaluate the performance of the octopoles. The switching dipole which directs the beam to339
the injection line of the FFA in Stage 2 will be located between the second octupole and the collimator,340
requiring the octupole to be ramped down for Stage 2 operation.341
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Figure 4. Horizontal (solid lines) and vertical (dashed lines) beam sizes through the in vitro beam transport,
simulated with space-charge in GPT (green), and without space-charge in MADX (red) and BDSIM (blue).
The vertical arc uses transparent optics in an achromat matching section to ensure that the first-order342
transfer map through the arc is equivalent to the identity transformation and that any dispersive effects are343
cancelled. A 2 m drift tube is added after the arc to penetrate the concrete shielding of the end station floor344
and to bring the beam to bench height. The abort line consists of a drift followed by a beam dump and345
requires the first vertical dipole to ramp down, preventing charged-particle transportation to the end station.346
The underlying physics of plasma-lens operation cannot be simulated in BDSIM or GPT, however it347
can be approximated using solenoid magnets of equivalent strength. RF cavity fields were not simulated.348
10 000 particles were simulated corresponding to the estimated maximum bunch charge of 1× 109 protons.349
Figure 4 shows excellent agreement between horizontal and vertical transverse beam sizes in BDSIM350
and MADX, verifying the beam line’s performance in the absence of space-charge effects. Reasonable351
agreement between BDSIM and GPT is also seen when space-charge forces are included in GPT. Emittance352
growth is observed prior to the first solenoid, affecting the optical parameters throughout the machine.353
However, the resulting beam dimensions at the cell layer of 1.38 cm horizontally and 1.47 cm vertically354
are not significantly different from the ideal beam in BDSIM. Further adjustments of the Gabor lenses355
and arc-quadrupole strengths may compensate for this. The transmission efficiency of the beam line is356
approximately 100%.357
The small bunch dimensions in both transverse planes at the focus after the third Gabor lens, where358
the energy selection collimator will be placed, remain a concern if the effect of space-charge has been359
underestimated. Similar bunch dimensions are achieved in the vertical arc, however, quadrupolar focusing360
is confined to a single plane mitigating further emittance growth.361
To investigate beam uniformity, BDSIM simulations with and without octupoles and collimation for362
beam shaping were conducted. Each octopole was assumed to have a magnetic length of 0.1 m and pole-tip363
radius of 5 cm. The strength parameter, k3, of each octupole was arbitrarily set to 6000. A 2 cm thick iron364
collimator with a 40 mm diameter aperture was positioned 1.5 m downstream of the octupole. Figure 5365
shows the beam phase-space and particle distributions at the end station for the transverse and longitudinal366
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(a) (b) (c)
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Figure 5. Beam phase space distributions at the end-station in the transverse plane, (X, Y ); X′ and Y′
give the slope relative to the Z axis. The transverse phase space is shown in figures a and b for simulations
without octupolar focusing and collimation, with the kinetic energy distribution shown in c. The same
phase space distributions simulated with the effect of octupoles and collimation are in figures d, e, and f.
axes with and without beam shaping. Without octupoles, the spatial profile is Gaussian, as expected,367
however, beam uniformity is improved with octupoles and collimation. The total beam width is 3.58 cm368
horizontally and 3.46 cm vertically, which is sufficient to irradiate one well in a six-well cell-culture plate.369
Further optimisation is required to improve uniformity whilst optimising beam-line transmission, which is370
approximately 70% for the results presented in figure 5. An aberration can be seen in both transverse planes371
with and without beam shaping. This effect originates upstream of the octupoles in the solenoids, and372
persists through to the end station. These aberrations are a concern. Future simulation efforts will replace373
the solenoids with a full electromagnetic simulation of the Gabor lens. This change is likely to change the374
aberrations. The non-Gaussian energy distribution without beam shaping is a result of space-charge forces375
at the ion source; the distribution persists to the end station as no components which affect the longitudinal376
phase space were simulated. The Gaussian distribution seen with beam shaping is due to collimation.377
The proposed design is capable of delivering beams of the desired size to the in vitro end station. Space-378
charge effects impact the beam-transport performance but it is believed that these can be mitigated with379
minor adjustments to the Gabor lenses in the capture section. Initial studies indicate that a uniform beam380
can be delivered with further optimisation of the octupoles and collimator.381
382
3.3.1 Alternative Design383
To mitigate potential emittance growth from space-charge forces, an alternative beam line design was384
developed in which the final two Gabor lenses in the matching and energy selection section are replaced by385
four quadrupoles, limiting any bunch focusing to one plane at a time. The resulting machine is reduced386
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in length to 15.4 m. Without space-charge effects, a beam width of 2.5 mm at the end station can be387
achieved. With space-charge, emittance growth prior to the first solenoid is once again observed leading388
to an increased beam size at the entrance of the first quadrupole, resulting in a spatially asymmetric and389
divergent beam at the end station. It is believed that the space-charge effects can be compensated by390
applying the same Gabor-lens optimisation as in the baseline design and adjusting the quadrupole settings391
to deliver beam parameters similar to those achieved in the absence of space charge. The alternative design392
provides a solution that is more resilient to space-charge effects than the baseline, however, only the lower393
bound on the desired beam size has been achieved so far. Further optimisation is required not only to394
optimise optical performance but also to optimise octupole settings and to determine whether a beam with395
the desired uniformity can be delivered to the end station.396
397
3.4 Post-acceleration and beam delivery to the in vitro and in vivo end stations398
A fixed-field alternating-gradient accelerator (FFA), based on the spiral scaling principle [Krest et al.399
(1956); Symon et al. (1956); Fourrier et al. (2008); Tanigaki et al. (2006)], will be used to accelerate the400
beam in LhARA Stage 2 to obtain energies greater than the 15 MeV protons and 4 MeV/u carbon (C6+)401
ions delivered by the laser-driven source. FFAs have many advantages for both medical and radiobiological402
applications such as: the capability to deliver high and variable dose; rapid cycling with repetition rates403
ranging from 10 Hz to 100 Hz or beyond; and the ability to deliver various beam energies without the use404
of energy degraders. An FFA is relatively compact due to the use of combined function magnets, which405
lowers the overall cost compared to conventional accelerators capable of delivering beams at a variety of406
energies such as synchrotrons. Extraction can be both simple and efficient and it is possible for multiple407
extraction ports to be provided. Furthermore, FFAs can accelerate multiple ion species, which is very408
important for radiobiological experiments and typically very difficult to achieve with cyclotrons.409
A typical FFA is able to increase the beam momentum by a factor of three, though a greater factor may410
be achieved. For LhARA, this translates to a maximum proton-beam energy of 127 MeV from an injected411
beam of 15 MeV. For carbon ions (C6+) with the same rigidity, a maximum energy of approximately412
33.4 MeV/u can be produced.413
The energy at injection into the FFA determines the beam energy at extraction. The injection energy will414
be changed by varying the focusing strengths in the Stage 1 beam line from the capture section through to415
the extraction line and the FFA ring. Appropriate adjustments to the frequency and phase of the RF in the416
FFA ring will also be made. This will allow the appropriate energy slice from the broad energy spectrum417
produced at the laser-driven source to be captured and transported to the FFA. The FFA will then accelerate418
the beam, acting as a three-fold momentum multiplier. This scheme simplifies the injection and extraction419
systems since their geometry and location can be kept constant.420
A second, ‘high-energy’, in vitro end station will be served by proton beams with a kinetic energy in the421
range 15–127 MeV and carbon-ion beams with energies up to 33.4 MeV/u. The extraction line from the422
FFA leads to a 90◦ vertical arc to send the beam to the high-energy in vitro end station. If the first dipole of423
the arc is not energised, the beam will be sent to the in vivo end station. The extraction line of the FFA424
includes a switching dipole that will send the beam to the high-energy-beam dump if it is not energised.425
The detailed design of the high-energy abort line, taking into account the requirement that stray radiation426
does not enter the end stations, will be performed as part of the LhARA R&D programme.427
428
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Figure 6. Twiss βx and βy functions and dispersion in the beam line consisting of the modified Stage 1
lattice and the transfer line allowing injection of the beam into the FFA ring. S goes from the laser target to
the exit of the injection septum.
3.4.1 Injection line429
The settings of the Stage 1 beam line need to be adjusted to reduce the Twiss β function propagating430
through the injection line to allow the beam to be injected into the FFA ring. The optical parameters in the431
Stage 1 beam line after adjustment are shown in figure 6. The beam is diverted by a switching dipole into432
the injection line which transports the beam to the injection septum magnet. The injection line matches433
the Twiss β functions in both transverse planes and the dispersion of the beam to the values dictated by434
the periodic conditions in the FFA cell (figure 6). The presence of dispersion in the injection line allows a435
collimator to be installed for momentum selection before injection. The beam is injected from the inside of436
the ring, which requires the injection line to cross one of the straight sections between the FFA magnets,437
see figure 7.438
439
3.4.2 FFA ring440
The magnetic field, By, in the median plane of a scaling spiral FFA is given by [Krest et al. (1956); Symon441
et al. (1956); Fourrier et al. (2008)]:442
By = B0
[
R
R0
]k
F
(
θ − ln
[
R
R0
]
tan ζ
)
; (3)
where B0 is the magnetic field at radius R0, k is the field index, ζ corresponds to the spiral angle and F443
is the ‘flutter function’. This field law defines a zero-chromaticity condition, which means the working444
point of the machine is independent of energy up to field errors and alignment imperfections. This avoids445
crossing any resonances, which would reduce the beam quality and may lead to beam loss.446
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Figure 7. The layout of the injection line from the switching dipole to the injection septum together with
the FFA ring, some of its subsystems and the first part of the extraction line.
Table 2 gives the main design parameters of the FFA ring. The ring consists of ten symmetric cells each447
containing a single combined-function spiral magnet. The choice of the number of cells is a compromise448
between the size of the orbit excursion, which dictates the radial extent of the magnet, and the length of the449
straight sections required to accommodate the injection and extraction systems.450
The betatron functions and dispersion in one lattice cell at injection are shown in figure 8a. The tune451
diagram, showing the position of the working point of the machine in relation to the main resonance452
lines, is shown in figure 8b. Tracking studies were performed using a step-wise tracking code in which the453
magnetic field is integrated using a Runge-Kutta algorithm [Lagrange et al. (2018)]. The magnetic field in454
the median plane was obtained using the ideal scaling law (equation 3). Enge functions were used to give455
the fringe fields. The field out of the median plane was obtained using Maxwell’s equations and a 6th-order456
Taylor expansion of the field. The dynamic acceptance for 100 turns, shown for the horizontal and vertical457
planes in figures 8c and 8d, respectively, are significantly larger than the beam emittance. This statement458
holds even if the most pessimistic scenario, in which the emittance is assumed to be ten times larger than459
nominal. These results confirm that a good machine working point has been chosen.460
A full aperture, fast injection of the beam will be performed using a magnetic septum, installed on the461
inside of the ring, followed by a kicker magnet situated in a consecutive lattice cell, as shown in figure 7.462
The specifications of the injection system are dictated by the parameters of the beam at injection, which are463
summarised for the nominal proton beam in table 3. The beam at injection has a relatively small emittance464
and short bunch length, which limits the intensity accepted by the ring due to the space-charge effect. An465
intensity of approximately 109 protons will be accepted by the ring assuming the nominal beam parameters.466
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Figure 8. Beam optics and tracking in the FFA. Twiss βh (blue), βv (purple) functions and dispersion
(green) in one lattice cell of the FFA ring (a). The working point of the FFA ring at (2.83, 1.22) on the tune
diagram (b). The results of the horizontal (c) and vertical (d) dynamical acceptance study in the FFA ring,
where a 1 mm offset is assumed in the vertical and horizontal planes respectively.
Table 3. Summary of the main parameters for the proton beam at the injection to the FFA ring. These
parameters correspond to the nominal (maximum) acceleration mode of operation.
Parameter Unit Value
Beam energy MeV 15
Total relative energy spread % ±2
Nominal physical RMS emittance (both planes) pim rad 4.1× 10−7
Incoherent space charge tune shift −0.8
Bunching factor 0.023
Total bunch length ns 8.1
Bunch intensity 109
Space-charge effects will be severe immediately after injection, but will quickly be reduced due to the467
debunching of the beam. Fast extraction of the beam over the full aperture will be performed using a kicker468
magnet followed by a magnetic septum installed in a consecutive lattice cell close to the extraction orbit.469
Acceleration of the beam to 127 MeV will be done using an RF system operating at harmonic number470
h = 1 with an RF frequency range from 2.89 MHz to 6.48 MHz. The RF voltage required for 10 Hz471
operation is 0.5 kV. However, at such a low voltage the energy acceptance at injection will be limited to472
±0.7% so a voltage of 4 kV is required to increase the energy acceptance to ±2%. This voltage can be473
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Table 4. Beam emittance values and target β values for different beam sizes for 40 MeV and 127 MeV
beams. The beam size is taken to be four times the sigma of the transverse beam distribution.
40 MeV protons 127 MeV protons 127 MeV protons
(Nominal) (Nominal) (Pessimistic)
RMS Emittance (x, y) [pi mm mrad] 0.137 0.137 1.37
β [m] for a 1 mm spot size 0.46 0.46 0.039
β [m] for a 10 mm spot size 46 46 4.5
β [m] for a 30 mm spot size 410 410 40
achieved with one cavity [Yonemura et al. (2008)]. Here, two cavities areused to provide greater operational474
stability. Normal conducting spiral-scaling FFA magnets, similar to the ones needed for LhARA, have been475
constructed successfully [Tanigaki et al. (2006); Planche et al. (2009)] using either distributed, individually-476
powered coils on a flat pole piece or using a conventional gap-shaping technique. For the LhARA FFA, we477
propose a variation of the coil-dominated design recently proposed at the Rutherford Appleton Laboratory478
in R&D studies for the upgrade of the ISIS neutron and muon source. In this case, the nominal scaling field479
is achieved using a distribution of single-powered windings on a flat pole piece. The parameter k can then480
be tuned using up to three additional independently-powered windings. The extent of the fringe field across481
the radius of the magnet must be carefully controlled using a ‘field clamp’ to achieve zero-chromaticity.482
An active clamp, in which additional windings are placed around one end of the magnet, may be used to483
control the flutter function and thereby vary independently the vertical tune of the FFA ring. The FFA is484
required to deliver beams over a range of energy; each energy requiring a particular setting for the ring485
magnets. Therefore, a laminated magnet design may be required to reduce the time required to change the486
field. The magnet gap of 4.7 cm given in table 2 is estimated assuming a flat-pole design for the magnet.487
488
3.4.3 Extraction Line489
Substantial margins in the beam parameters were assumed in the design of the extraction line from the490
FFA due to uncertainties in the beam distributions originating from: the Stage 1 beam transport; the491
FFA injection line; and potential distortions introduced by the presence of space-charge effects during492
acceleration in the ring. Therefore, the beam emittance was allowed, pessimistically, to be as large as a493
factor of ten greater than the nominal value, which was derived assuming that the normalised emittance494
is conserved from the source, through the Stage 1 beam line, and in the FFA ring. In the nominal case,495
the physical emittance of the beam is affected by adiabatic damping only. Substantial flexibility in the496
optics of the extraction line is required, as the extraction line must accommodate a wide spectrum of beam497
conditions to serve the in vitro and in vivo end-stations.498
Detailed studies were carried out for proton beams with kinetic energies of 40 MeV and 127 MeV. Table499
4 gives the Twiss β values for different beam sizes for the 40 MeV and 127 MeV proton-beam scenarios500
assuming a Gaussian beam distribution. The optics and geometric acceptance of the system is approximately501
the same for the 40 MeV and 127 MeV beams. This justified the working hypothesis that beam emittance is502
approximately the same for both beam energies. This assumption will be revised as soon as space-charge503
simulations for the entire system are available.504
The first two dipoles and four quadrupoles of the extraction line bend the beam coming from the extraction505
septum of the FFA such that it is parallel to the low-energy beam line while ensuring that dispersion is506
closed. Closing the dispersion is critical as off-momentum particles will follow trajectories different to507
those followed by particles with the design momentum and therefore impact the size and shape of the beam508
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Figure 9. Comparison of MAD-X and BDSIM simulation of 40 MeV (left) and nominal 127 MeV (right)
proton beam passing through the high energy in vitro arc simulated with 104 particles (in BDSIM).
downstream. The second part of the extraction line consists of four quadrupoles which transport the beam509
either to the first dipole of the vertical arc that serves the high-energy in vitro end station or to the in vivo510
end-station if this dipole is not energised. These quadrupoles provide the flexibility required to produce the511
different beam sizes for the in vitro end station as specified in table 4.512
513
3.4.4 High-energy in vitro beam line514
The high-energy in vitro beam line transports the beam from the exit of the extraction line and delivers it to515
the high-energy in vitro end station. The 90◦ vertical bend is a scaled version of the low-energy vertical arc,516
following the same design principles, and also consists of two bending dipole magnets and six quadrupole517
magnets. To accommodate the higher beam energies, the lengths of the magnets were scaled in order to518
ensure that peak magnetic fields were below the saturation limits of normal conducting magnets. The519
bending dipole magnet lengths were increased to 1.2 m each and the quadrupole lengths were tripled to520
0.3 m each. The overall length of the arc then becomes 6 m, compared to 4.6 m for the low energy in vitro521
arc. This difference in arc length means the high-energy in vitro arc finishes about 0.9 m higher than the522
low-energy one. This difference can easily be accommodated by adjusting the final drift lengths.523
The quadrupole strengths for the scaled high-energy in vitro arc were obtained using MADX and tracking524
simulations using BDSIM show good agreement, see figure 9. The input beam distribution used in BDSIM525
was assumed to be Gaussian with Twiss β = 46, which gives a beam size of about 10 mm. Small deviations526
from the BDSIM results were observed in GPT simulations due to space-charge effects.527
528
3.4.5 In vivo beam line529
To facilitate efficient small-animal handling, an end station dedicated to in vivo experiments has been530
positioned adjacent to the principle road access to the facility. If the first dipole of the high-energy in vitro531
arc is not energised, the beam is sent to the in vivo end station. From the end of the extraction line, 7.7 m of532
drift is necessary to clear the first bending dipole of the in vitro arc, to provide space for the five RF cavities533
needed for longitudinal phase-space manipulation and to allow space for diagnostic devices. Following this534
drift is a further 6.6 m of beam line that includes four quadrupoles, each of length 0.4 m, which are used to535
perform the final focusing adjustments of the beam delivered to the in vivo end station. A final 1.5 m drift536
length at the end is reserved for scanning magnets to be installed to perform spot scanning and to penetrate537
the shielding of the in vivo end station. In total the in vivo beam line is 15.6 m in length.538
The design is flexible in matching the various βx,y values given in table 4, but is not able to match the539
smallest target value of βx,y = 0.039m for the pessimistic scenario, which is very challenging. To verify540
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Figure 10. MAD-X and BDSIM simulations of the in vivo beam line for a 40 MeV proton beam (top row)
and a nominal 127 MeV proton beam (bottom row) with quadrupoles matched to βx,y = 0.46m (left),
βx,y = 46m (middle) and βx,y = 410m (right) for 104 particles.
that the optics design could provide the required beam sizes, simulations were performed with BDSIM541
using an input Gaussian beam generated with the Twiss β values given in tables 4. Figure 10 shows the542
results of simulations for a 40 MeV proton beam and a nominal emittance 127 MeV proton beam matched543
in order to obtain beam sizes of 1 mm, 10 mm and 30 mm.544
545
3.5 Instrumentation546
Commercial off-the-shelf (COTS) instrumentation will be used for Stages 1 and 2 of LhARA wherever547
possible. However, the characteristics of the beam (e.g. very high charge-per-bunch, low-to-moderate548
energy) will require some custom solutions to be developed. The authors are developing two concepts,549
termed SciWire and SmartPhantom, for the low- and high-energy in vitro end stations respectively. These550
detectors can also be used for beam diagnostics. This new instrumentation may find application at other551
facilities. Instrumentation for the detection of secondary particles arising from the interaction of the beam552
with tissue is not discussed here but is an important area that will be studied in the future.553
554
3.5.1 SciWire555
For the Stage 1 beam, the maximum proton energy is 15 MeV. Shot-to-shot characterisation of the beam is556
essential and requires the use of a very thin detector with a fast response. The SciWire [Kurup (2019)] is557
being developed to provide energy and intensity profile measurements for low-energy ion beams. A single558
SciWire plane consists of two layers of 250µm square-section scintillating fibres, with the fibre directions559
in the two layers orthogonal to each other. A series of back-to-back planes provides a homogeneous volume560
of scintillator. If there are enough planes to stop the beam, the depth of penetration will allow the beam561
energy to be inferred. This is obviously a destructive measurement so would only be performed when562
experiments are not running. A single plane, however, can be used for 2D beam-profile measurements at563
the same time that beam is delivered for experiments. Detection of the light from SciWire fibres may be by564
CMOS camera, or using photodiodes. If the instrumentation is sufficiently fast, the SciWire can be used to565
derive feedback signals for beam tuning.566
567
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3.5.2 SmartPhantom568
To study in real time the dose profile of Stage 2 beams, the SmartPhantom [Barber (2018)] is being569
developed. This is a water-filled phantom, instrumented with planes of scintillating fibres, used to infer570
the dose distribution with distance. The detection elements of the SmartPhantom are 250µm diameter,571
round, scintillating fibres. Each fibre station consists of two planes of fibres, in which the fibre directions572
are orthogonal. Five fibre stations are arranged in the phantom in front of the cell-culture flask. The fibres573
may be coupled to photodiodes, or a CMOS camera. Simulations in GEANT4 are being used to develop574
analysis techniques to determine the position of the Bragg peak shot-by-shot. The beam profile and dose575
delivered can then be calculated in real time.576
577
3.5.3 Beam line Instrumentation578
The instrumentation requirement begins with the Ti:Sapphire laser. The laser focal spot will be characterised579
using a camera-based system and high-speed wavefront measurements [Wang (2014)] from COTS vendors.580
For the Stage 1 beam line, beam position monitors (BPMs) will be needed for beam steering. Because581
of the low beam energy, non-intercepting BPMs using capacitive pickup buttons will be used. Custom582
pickups will be needed to match the beam pipe geometry but COTS electronics are available. The beam583
current will be monitored near the end of each beam line, using integrating current toroids (ICT), backed584
up with the option of insertable multi-layer Faraday cups (MLFC) to give absolute beam current and energy585
measurements. Beam profiles could be measured by SEM grids on both Stage 1 and Stage 2 beam lines.586
For Stage 1, these monitors will be mounted on pneumatic actuators to avoid scattering. Each end station587
could be equipped with insertable “pepper-pot” emittance monitors and a transverse deflection cavity with588
fluorescent screen could be provided for bunch shape measurements.589
The BPMs on the FFA will require pickup designs suitable for the unusual, wide and shallow vacuum590
vessel. The FFA at the KURNS facility in Kyoto is of a similar layout [Uesugi (2018)] and uses a kicker591
and capacitive pickup to perform tune measurements in each transverse direction. A minimum of one BPM592
every second cell will be used in the FFA so that the beam orbit can be measured. BPMs will also be593
required close to the injection and extraction septa. The BPM system may be able to use COTS electronics,594
but the pickups will be based on the KURNS design of multiple electrodes arranged across the vacuum595
vessel width.596
The data acquisition system needs to be able to store calibration data and apply corrections in real time. It597
is necessary to be able to find the beam centre from a profile, even when the profile may be non-Gaussian598
and possibly asymmetric. Field programmable gate arrays (FPGAs) can be used to perform fast fitting and599
pattern recognition of beam profiles. The instrumentation will be integrated with the accelerator control600
system to be able to provide fast feedback and adjustment of the beam parameters in real time.601
602
3.6 Biological end stations603
In order to deliver a successful radiobiological research programme, high-end and fully equipped in vitro604
and in vivo end-stations will be housed within the LhARA facility. The two in vitro end-stations (high605
and low energy) will contain vertically-delivered beam lines which will be used for the irradiation of 2D606
monolayer and 3D-cell systems (spheroids and patient-derived organoids) in culture. The beam line within607
the end-stations will be housed in sealed units that will be directly sourced with appropriate gases (carbon608
dioxide and nitrogen), allowing for the cells within culture plates to be incubated for a short time in stable609
conditions prior to and during irradiation. This will also enable the chamber to act, where necessary, as a610
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hypoxia unit (0.1%–5% oxygen concentration). Furthermore, these sealed units will contain robotics to611
enable the numerous cell culture plates housed within to be placed into and taken out of the beam.612
The in vitro end-stations will be located within a research laboratory equipped with up-to-date and613
state-of-the-art facilities. The laboratory will include all the vital equipment for bench-top science, sample614
processing and analysis (e.g. refrigerated centrifuges and light/fluorescent microscopes), along with the615
equipment required for contaminant-free cell culture (e.g. humidified CO2 cell culture incubators, Class II616
biological safety cabinets), and for the storage of biological samples and specimens (e.g.−20◦C and−80◦C617
freezers and fridges). The laboratory will also house an X-ray irradiator (allowing direct RBE comparisons618
between conventional photon irradiation, and the proton and carbon ions delivered by the accelerator),619
hypoxia chamber (for long-term hypoxia studies), a robotic workstation (handling and processing of large620
sample numbers, assisting in high-throughput screening experiments), and an ultra-pure-water delivery621
system. These facilities will enable a myriad of biological end-points to be investigated in both normal- and622
tumour-cell models not only from routine clonogenic survival and growth assays, but also from significantly623
more complex end-points (e.g. inflammation, angiogenesis, senescence and autophagy).624
The in vivo end-station will be served with high-energy proton and carbon ions capable of penetrating625
deeper into tissues allowing the irradiation of whole animals. The ability to perform in vivo pre-clinical626
studies is vital for the future effective translation of the research into human cancer patients where optimum627
treatment strategies and the reduction of side-effects are crucial. The in vivo end-station will allow the628
irradiation of a number of small-animal models (e.g. xenograft mouse and rat models) which can further629
promote an examination of particular ions on the appropriate biological end-points (e.g. tumour growth630
and normal tissue responses). The end-station will contain a small-animal handling area which will allow631
for the anaesthetisation of animals prior to irradiation. To enable the irradiation of small target volumes632
with a high level of precision and accuracy, an image guidance system (e.g. computed tomography) will be633
available. The animals will subsequently be placed in temperature-controlled holder tubes enabling the634
correct positioning of the relevant irradiation area in front of the beam line. The beam size is sufficient to635
give flexibility in the different irradiation conditions, in particular through passive scattering, pencil-beam636
scanning, and micro-beam irradiation, to be investigated at both conventional and FLASH dose rates. It is637
envisaged that the animals will be taken off-site post-irradiation to a nearby animal-holding facility for a638
follow-up period where biological measurements will be conducted.639
640
3.7 Infrastructure and integration641
The LhARA facility will encompass two floors of roughly 42 m in length and 18 m wide. The ground floor642
will contain the laser, accelerator, and in vivo end station while the first floor will house the laboratory area643
and the two in vitro end stations. The entire facility will require radiation protection in the form of concrete644
shielding. There will be three principal areas: a radiation controlled-access area, a laser controlled-access645
area, and a laboratory limited-access area.646
For a facility such as LhARA, laser, radiation and biological safety are primary concerns. It is envisaged647
that LhARA will be built at a national Laboratory or equivalent research institute which has an established648
safety-management system and culture in place.649
The infrastructure and integration of the LhARA facility will require R&D in four key areas: risk analysis650
(project risks), risk assessments (safety risks), radiation simulations, and controls development. The risk651
analysis will cover all aspects of the facility, such as funding and resource availability, not just technical652
risks. A safety-risk assessment will be performed to describe and control all potential safety risks in the653
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Figure 11. Energy loss as a function of depth in the low-energy in vitro end station for three mono-
energetic proton energies: 10 MeV; 12 MeV; and 15 MeV. Each beam was simulated using 104 particles at
the start of the simulated end station. The material through which the beam passes is indicated above the
figure. The entrance window is plotted at a Depth value of 0 m. The beam deposits energy in the beam
window and the layer of scintillating fibre before passing through the air and entering the sample container.
facility. The safety-risk assessment will, to a reasonable degree, identify all pieces of equipment that654
require safety mitigations and identify control measures that must be put in place. Coupled closely with the655
safety-risk assessment, radiation simulations will be developed to characterise the radiation hazards in and656
around the LhARA facility. The last area to require R&D will be the control systems. It is expected that the657
facility will use the Experimental Physics and Industrial Control System, which can be further developed658
at this stage.659
660
4 PERFORMANCE
The dose distributions delivered to the end stations were evaluated using BDSIM. Figure 11 shows the661
energy lost by the beam as it enters the low-energy in vitro end station. The beam passes through the662
vacuum window, a layer of scintillating fibre, and a 5 mm air gap. The beam then enters the cell-sample663
container, assumed to be polystyrene, which supports a 30µm thick layer of cells, modelled using the664
Geant4 material “G4 SKIN ICRP” [NIST (2017)]. The transverse momentum of protons in the beam was665
assumed to be Gaussian distributed, with a lateral spread small enough for the beam to be fully contained666
within the required spot size of 3 cm. Figure 11 shows that a proton beam with 10 MeV kinetic energy667
does not reach the cell. The Bragg peak of a 12 MeV proton beam is located close to the cell layer, while668
a 15 MeV beam, the maximum energy specified for delivery to the low-energy in vitro end station, has669
a Bragg peak located beyond the cell layer. LhARA’s ability to deliver various energies will allow the670
investigation of radiobiological effects for irradiations using different parts of the Bragg peak, effectively671
varying the LET across the sample. RF cavities are placed in both the stage 1 and the stage 2 beam lines to672
allow the manipulation of the energy of the bunch as a function of time. This facility will allow the study673
of the impact of a “spread-out Bragg peak” (SOBP).674
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The maximum dose that can be delivered was evaluated for a variety of beam energies. In order for675
the dose to be reported in units of Gray it is necessary to define the volume within which the energy676
deposition is to be integrated. Therefore, the dose was estimated from simulations by calculating the energy677
deposited in a volume of water corresponding in size to the sensitive volume of a PTW 23343 Markus ion678
chamber [PTW (2019/2020)] placed at the position of the Bragg peak in each case. This choice allows the679
doses and dose-rates reported below to be compared to other facilities which are in operation, since the680
PTW 23343 Markus ion chamber is widely used at existing facilities. The cylindrical sensitive volume of681
the ion chamber has a radius of 2.65 mm and a depth of 2 mm, giving a volume of about 4.4× 10−8 m3.682
The total energy deposited within the chamber was recorded and converted into dose in units of Gray.683
For the low-energy in vitro end station, the minimum spot size is specified to have a diameter of 10 mm,684
which is larger than the area of the chamber. A single shot of 109 protons at 12 MeV with the minimum685
design spot size deposits 3.1× 10−4 J in the chamber volume, corresponding to a dose of 7.1Gy. For this686
simulation, the thickness of the sample container was reduced so that the Bragg peak could be positioned687
within the chamber volume. For the bunch length of 7.0 ns, the maximum instantaneous dose rate is688
1.0× 109 Gy/s and the average dose rate is 71Gy/s, assuming a repetition rate of 10 Hz. A single shot of689
109 protons at 15 MeV deposits 5.6× 10−4 J in the chamber volume, corresponding to a dose of 12.8Gy.690
This gives an instantaneous dose rate of 1.8× 109 Gy/s and an average dose rate of 128Gy/s assuming the691
same bunch length and repetition rate as for the 12 MeV case.692
For the high-energy in vitro end station, a different setup was used for high energy proton beams. A693
similar design to the low-energy end station was used but with the air gap increased from 5 mm to 5 cm and694
a water phantom was placed at the end of the air gap instead of a cell culture plate. The water phantom695
used in the simulation was based upon the PTC T41023 water phantom [PTW (2009)]. In addition, the696
smaller minimum design beam size of 1 mm was used. A single shot of 109 protons at 127 MeV deposits697
6.9 × 10−4 J in the chamber at the pristine Bragg peak depth corresponding to a dose of 15.6Gy, an698
instantaneous dose rate of 3.8 × 108 Gy/s and an average dose rate of 156Gy/s. The end-station design699
assumed for a 33.4 MeV/u carbon beam was the same as that used for the low-energy in vitro end station700
due to the limited range in water of the carbon beam. The intensity of the beam is a factor of 12 less than701
for protons in order to preserve the same strength of the space-charge effect at injection into the FFA with702
the same beam parameters, as the incoherent space charge tune shift is proportional to q2/A and inversely703
proportional to β2γ3, where q corresponds to the particle charge, A its mass number, and β and γ its704
relativistic parameters. A single pulse of 8.3× 107 ions deposits 3.2× 10−3 J at the depth of the pristine705
Bragg peak, leading to an instantaneous dose rate of 9.7× 108 Gy/s and a maximum average dose rate of706
730Gy/s.707
The expected maximum dose rates are summarised in table 5. The instantaneous dose rates depend on the708
bunch length which differs depending on the energies. For the low-energy in vitro line, a 7 ns bunch length709
is assumed for all energies. For the higher energies, a 127 MeV proton beam is delivered with a bunch710
length of 41.5 ns, and a bunch length of 75.2 ns for a 33.4 MeV/u carbon beam. The same repetition rate of711
10 Hz was used for all energies. The minimum beam size at the start of the end station for the 12 MeV and712
15 MeV proton-beam simulations was 1 cm. A 1 mm beam size was used for the 127 MeV proton beam and713
33.4 MeV/u carbon-ion beam simulations.714
715
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Table 5. Summary of expected maximum dose per pulse and dose rates that LhARA can deliver for
minimum beam sizes. These estimates are based on Monte Carlo simulations using a bunch length of
7 ns for 12 MeV and 15 MeV proton beams, 41.5 ns for the 127 MeV proton beam and 75.2 ns for the
33.4 MeV/u carbon beam. The average dose rate is based on the 10 Hz repetition rate of the laser source.
12 MeV Protons 15 MeV Protons 127 MeV Protons 33.4 MeV/u Carbon
Dose per pulse 7.1Gy 12.8Gy 15.6Gy 73.0Gy
Instantaneous dose rate 1.0× 109 Gy/s 1.8× 109 Gy/s 3.8× 108 Gy/s 9.7× 108 Gy/s
Average dose rate 71Gy/s 128Gy/s 156Gy/s 730Gy/s
5 CONCLUSIONS
The initial conceptual design of LhARA, the Laser-hybrid Accelerator for Radiobiological Applications,716
has been described and its performance evaluated in simulations that take into account the key features of717
the facility. LhARA combines a laser-driven source to create a large flux of protons or light ions which are718
captured and formed into a beam by strong-focusing plasma lenses thus evading the current space-charge719
limit on the instantaneous dose rate that can be delivered. Acceleration, performed using a fixed-field720
alternating-gradient accelerator, preserves the unique flexibility in the time, spectral, and spatial structure721
of the beam afforded by the laser-driven source. The ability to trigger the laser pulse that initiates the722
production of protons or ions at LhARA will allow the time structure of the beam to be varied to interrupt723
the chemical and biological pathways that determine the biological response to ionising radiation. In724
addition, the almost parallel beam that LhARA will deliver can be varied to illuminate a circular area with725
a maximum diameter of between 1 cm and 3 cm with an almost uniform dose or focused to a spot with726
diameter of ∼ 1mm. These features make LhARA the an extremely flexible tool for the systematic study727
of the radiobiology of proton and ion beams.728
The laser-hybrid approach, therefore, will allow radiobiological studies and eventually radiotherapy to729
be carried out in completely new regimes, delivering a variety of ion species in a broad range of time730
structures and spatial configurations at instantaneous dose rates up to and potentially significantly beyond731
the current ultra-high dose-rate “FLASH” regime. By demonstrating a triggerable system that incorporates732
dose-deposition imaging in the fast feedback-and-control system. In the long term, LhARA has the potential733
to remove the requirement for a large gantry and so lay the foundations for “best in class” treatments to be734
made available to the many by reducing the footprint of future particle-beam therapy systems.735
LhARA has the potential to drive a change in clinical practice in the medium term by increasing the736
wealth of radiobiological knowledge. This enhanced understanding in turn may be used to devise new737
approaches to decrease radio-toxicity on normal tissue while maintaining, or even enhancing, the tumour-738
control probability. The radiobiology programme in combination with the demonstration in operation of739
the laser-hybrid technique means that the execution of the LhARA programme has the potential to drive a740
step-change in the clinical practice of proton- and ion-beam therapy.741
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